Close Menu

NEW YORK (360Dx) – OptiScan Biomedical today announced its OptiScanner 6000 device for near-continuous glucose and lactate monitoring has received CE mark, allowing the firm to market it in the European Union.

The Hayward, California-based firm said it plans to launch the device later this year.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.